IGC - IGC Pharma Inc
Close
0.3596
0.005 1.363%
Share volume: 80,297
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$0.35
0.00
1.38%
Fundamental analysis
24%
Profitability
0%
Dept financing
4%
Liquidity
75%
Performance
40%
Performance
5 Days
-2.55%
1 Month
-18.66%
3 Months
-28.08%
6 Months
3.04%
1 Year
10.99%
2 Year
-34.62%
Key data
Stock price
$0.36
DAY RANGE
$0.34 - $0.36
52 WEEK RANGE
$0.25 - $0.91
52 WEEK CHANGE
$0.05
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Ram Mukunda
Region: US
Website: http://www.igcinc.us
Employees: 24
IPO year: -
Issue type: Common Stock
Market: NYSE American
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://www.igcinc.us
Employees: 24
IPO year: -
Issue type: Common Stock
Market: NYSE American
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
igc is developing a product portfolio of phytocannabinoid-based therapies through leading edge research for the treatment of a wide range of therapeutic indications. these include neuropathic and cancer pain, epilepsy, end of life supportive care, adjunctive supportive therapies of chronic neurological and oncological diagnosis, which are life altering or life threatening our mission is to treat pain, ptsd, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions with phytocannabinoid-based treatments
Recent news